Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 16/20 | 0.93 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.73 |
| ▸ | AR | P10275 | 4/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878326 | 1.00 | PGR (0.93) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL6091320 | 0.99 | PGR (0.95) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5889060 | 0.83 | PGR (0.76) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5360104 | 0.78 | PGR (0.71) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5878671 | 0.78 | PGR (1.00) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5889137 | 0.78 | PGR (0.70) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5878865 | 0.77 | PGR (0.66) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5373396 | 0.77 | PGR (0.64) | PGRNR3C1ARNR3C2 | |
| SCHEMBL5889160 | 0.77 | PGR (0.67) | PGRNR3C1ARNR3C2ESR1 | |
| SCHEMBL5358795 | 0.76 | PGR (0.74) | PGRNR3C1ARNR3C2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006508076-A | — | — | 2006-03-09 | — | — | JP | claimed |
| EP-1551845-A1 | 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | claimed |
| WO-2004033460-A1 | 5-CYCLOALKENYL 5H-CHROMENO[3,4-F]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2004-04-22 | — | — | WO | claimed |
| US-20060194827-A1 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | LIGAND PHARMACEUTICALS, INCORPORATED | 2006-08-31 | — | — | US | disclosed |
| EP-1551845-A1 | 5-CYCLOALKENYL 5 i H /i -CHROMENO 3,4-F QUINOLINE DERIV ATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040152718-A1 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-08-05 | — | — | US | disclosed |
| WO-2004033460-A1 | 5-CYCLOALKENYL 5H-CHROMENO[3,4-F]QUINOLINE DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194827-A1 | 5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | PGR, GPER1, FSHR | PGR 1/4885NR3C1 13/4885AR 88/4885 |
| US-20040152718-A1 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds | PGR, GPER1, PGRMC2 | PGR 1/4885NR3C1 14/4885AR 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.